AKT1 and glioblastoma: In this context, our in vitro study, which focused on the intricate PTEN/PI3K/AKT/mTOR pathway, revealed interesting insights that might explain the reason for failure of numerous clinical trials, and suggest a new potential target to counteract not only GBM growth and invasiveness but also GSCs self-renewal.